Abstract
It is assumed that schizophrenia may consist of extremely heterogeneous group of phenotypes with different biological and neurochemical pathological mechanisms. At the same time, much attention is paid to the potential role of the immune system in the development of schizophrenia and, in particular, the participation of various cytokines in these processes. Interleukin-6 (IL-6) is one of the key regulators of inflammatory processes. A number of studies have previously reported changes in its levels in patients with schizophrenia. However, data on the specificity of these changes in the literature are much less well-documented and sometimes even contradictory. The dichotomous functioning of IL-6 may play a key role in the regulation of both pro- and anti-inflammatory processes. In this regard, the role of this cytokine in the etiopathogenesis of schizophrenia may depend on the phase of the disease and the context of the inflammatory process. The aim of this review was to analyze in detail the role of IL-6 in the mechanisms of schizophrenia and its potential impact on the course, diagnosis and therapy of this disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
